BVNKF - U.S. to widen access to monkeypox vaccines

The Biden Administration is planning to expand the availability of monkeypox vaccines as the health officials attempt to control a growing outbreak of the rare viral disease, usually found in Africa.

Accordingly, the Centers for Disease Control and Prevention (CDC) is recommending monkeypox shots for those with presumed exposure to the virus, not only for those with confirmed exposure.

The latest update includes men who have sex with men who have had multiple recent partners in venues where monkeypox virus was known to be spreading or areas where monkeypox is transmitting.

The U.S. is planning to rollout nearly 300,000 monkeypox vaccine doses including an immediate deployment of 56,000 doses of the Jynneos vaccine developed by Bavarian Nordic ( OTCPK:BVNKF ) ( OTCPK:BVNRY ). Another 240,000 doses of Jynneos will be released in the coming weeks.

Health and Human Services (HHS) expects to release a total of 1.6M doses of Jynneos vaccine throughout the year including more than 750,000 doses in the summer and 500,000 doses expected in the fall.

Local health departments will also be able to request ACAM2000 vaccine of Emergent BioSolutions ( NYSE: EBS ). The older generation monkeypox vaccine can cause significant side effects and it is not recommended for everyone.

CDC has reported 306 confirmed monkeypox cases in 27 states and Washington, D.C.

Last week, the World Health Organization decided that the current outbreak of monkeypox did not amount to a global public health emergency.

For further details see: